Avidity reports FTC granted request for early termination of HSR waiting period

In a regulatory filing, Avidity Biosciences (RNA) noted that as previously disclosed, the company entered into an Agreement and Plan of Merger, dated as of October 25, 2025, with Novartis AG (NVS). On December 17, the FTC granted a request for the early termination of the waiting period under the HSR Act. “The expiration of the waiting period under the HSR Act satisfies one of the conditions to the consummation of the Transactions. The consummation of the Transactions remains subject to completion of the separation of Atrium Therapeutics, Inc. from the Company and the satisfaction or waiver of other customary closing conditions as described in the preliminary proxy statement filed by the Company with the SEC, as amended,” the filing stated.